September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Anti-vegf Theraphy Versus Pdt in the Treatment of Cnv Secondary to Crsc
Author Affiliations & Notes
  • Giulia Caminiti
    Department of Ophthalmology, University Of Cagliari, Cagliari, Italy
  • Riccardo Saldì
    Department of Ophthalmology, University Of Cagliari, Cagliari, Italy
  • Giovanni M. Satta
    Department of Ophthalmology, University Of Cagliari, Cagliari, Italy
  • Beatrice Lobina
    Department of Ophthalmology, University Of Cagliari, Cagliari, Italy
  • Enrico Peiretti
    Department of Ophthalmology, University Of Cagliari, Cagliari, Italy
  • Footnotes
    Commercial Relationships   Giulia Caminiti, None; Riccardo Saldì, None; Giovanni M. Satta, None; Beatrice Lobina, None; Enrico Peiretti, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2149. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Giulia Caminiti, Riccardo Saldì, Giovanni M. Satta, Beatrice Lobina, Enrico Peiretti; Anti-vegf Theraphy Versus Pdt in the Treatment of Cnv Secondary to Crsc. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2149.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To describe a consecutive series of patients affected by chronic central serous chorioretinopathy (CRSC) complicated with choroidal neovascularization (CNV) treated with intravitreal injection (IVT) of anti-VEGF or photodynamic therapy (PDT).

Methods : 40 eyes of 34 consecutive patients have been followed for a minimum of 1 year and maximum of 7 years with an history of CRSC complicated with CNV. All the patients were evaluated with fluorescein, indocyanine angiography (FA, ICG) and OCT scan that revealed polypoidal lesions in 67% of the CNV. Patients were classified in 3 groups: the first group included 18 eyes treated with photodynamic therapy (PDT), the second group comprised 19 eyes treated with intravitreal injection (IVT) of anti-VEGF (Bevacizumab, Pegaptanib or Ranibizumab) and the third group involved 3 eyes treated with combination therapy (PDT + IVT). Each patient performed FA, ICG and OCT at the baseline and during the follow-up depending on the physician discretion. The fixed schedule for the follow-up was every 3 months for PDT, after 1,2 and 3 months for the IVT patients with a chance to extend the fixed visit to a maximum of 6 months. The third group had a follow-up similar to the first group.

Results : After 1 year of follow-up, the first group (only PDT) showed that 64% of the eyes had an improvement of best corrected visual acuity (BCVA), the 21% had stabilization and the remaining 15% had a worsening of VA, with a mean of 1.5 PDT sessions. In the second group of patients (IVT of anti-VEGF) 47% of the eyes had an improvement of BCVA, 33% had stabilization and 20% showed a reduction of VA, the mean average of IVT was 3.3. In third group of patients (PDT + IVT) 33% increased his BCVA, 33% no change and 33% had a reduction of BCVA, each patient performed a mean of 1.5 sessions of combination therapy.

Conclusions : Similarly, IVT of anti-VEGF and Photodynamic therapy as well, demonstrated to be efficacy in maintaining or improving BCVA in more than 65% of patients with CRSC complicated with CNV.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×